Buparlisib Completed Phase 2 Trials for Breast Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02404844Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer
NCT01923168Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
NCT01790932BKM120 For Triple Negative Breast Cancer
NCT01629615A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer